Samsung Biologics has announced a major expansion: the creation of a third biopharmaceutical campus in Songdo, Incheon, backed by a 7 trillion won investment.
This new campus will expand the company’s capabilities beyond its existing focus on antibody drug manufacturing. The plan is to house production and R&D facilities for next-generation modalities, including cell & gene therapies (CGT), antibody vaccines, peptides, and advanced biologics Songdo making Samsung Biologics a more diversified “bio-village.”
The company expects the expansion to create over 4,000 direct jobs by the project’s completion in 2034, alongside thousands more indirectly through partner companies and construction work.
According to CEO John Lim, this move aims to secure “new growth engines” and strengthen Samsung Biologics’ global competitiveness in the outsourcing drug-manufacturing business (CDMO).
With this investment, Samsung Biologics is signaling ambitions to not just expand capacity, but also to shape a wider, more technologically advanced biopharma hub a move likely to attract global clients and support advances in cutting-edge therapies.
Samsung Smartphone Business Faces Pressure as Exports Fall and Costs Rise 
Samsung Electronics and SK Hynix face record tax bills as South Korea’s chip boom fuels government revenue. 
Samsung’s 450 Trillion Won Semiconductor Expansion Plan Signals New Phase in Chip Manufacturing 
Samsung Reveals Ultra-Thin Galaxy S25 Edge as Apple Prepares iPhone ‘Air’ 
Samsung co-CEO Han Jong-Hee dies at 63 at Hospital